Full Text Journal Articles from
Abstract 31653108


Find full text journal articles

Caffeine and Clinical Outcomes in Premature Neonates.

PMID: 31653108 (view PubMed database entry)
DOI: 10.3390/children6110118 (read at publisher's website )
PMCID: PMC6915633 (free full text version available)

Download PDF Download PDF

Vasantha H S Kumar, Steven E Lipshultz,

Caffeine is the most widely used drug by both adults and children worldwide due to its ability to promote alertness and elevate moods. It is effective in the management of apnea of prematurity in premature infants. Caffeine for apnea of prematurity reduces the incidence of bronchopulmonary dysplasia in very-low-birth-weight infants and improves survival without neurodevelopmental disability at 18-21 months. Follow-up studies of the infants in the Caffeine for Apnea of Prematurity trial highlight the long-term safety of caffeine in these infants, especially relating to motor, behavioral, and intelligence skills. However, in animal models, exposure to caffeine during pregnancy and lactation adversely affects neuronal development and adult behavior of their offspring. Prenatal caffeine predisposes to intrauterine growth restriction and small growth for gestational age at birth. However, in-utero exposure to caffeine is also associated with excess growth, obesity, and cardio-metabolic changes in children. Caffeine therapy is a significant advance in newborn care, conferring immediate benefits in preterm neonates. Studies should help define the appropriate therapeutic window for caffeine treatment along with with the mechanisms relating to its beneficial effects on the brain and the lung. The long-term consequences of caffeine in adults born preterm are being studied and may depend on the ability of caffeine to modulate both the expression and the maturation of adenosine receptors in infants treated with caffeine.

Children (Basel) (Children (Basel, Switzerland))
[2019, 6(11):]

Cited: 0 times

AltMetric Statistics

Additional resources:


0.5802 s